At ACC 2025, new real-world safety data were presented on sotatercept, a novel fusion protein for pulmonary arterial ...

Travere Therapeutics, Inc., today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation (NKF) Spring ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Teacher Retirement System of Texas boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by ...

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

Raymond James Financial Inc. acquired a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free ...

DelveInsight's "ROCKLATAN/ROCLANDA Market Size, Forecast, and Market Insight Report" highlights the details around ...

It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and ...

Clazosentan – an intravenously-administered endothelin A receptor antagonist – is designed to prevent cerebral vasospasm in aSAH patients, a sudden narrowing of blood vessels that can occur in ...

Buying Chinook will add a pair of late clinical-stage programmes for IgAN, headed by atrasentan, an oral endothelin A receptor antagonist (ERA) in a phase 3 trial due to generate results later in ...

In an earlier trial, treatment with bosentan, an oral endothelin receptor antagonist, reduced the occurrence of new DUs by 48%. The present study (RAPIDS-2, for ‘RAndomized, double-blind, ...